345 related articles for article (PubMed ID: 28502502)
1. Dapagliflozin in patients with type II diabetes mellitus, with and without elevated triglyceride and reduced high-density lipoprotein cholesterol levels.
Bays HE; Sartipy P; Xu J; Sjöström CD; Underberg JA
J Clin Lipidol; 2017; 11(2):450-458.e1. PubMed ID: 28502502
[TBL] [Abstract][Full Text] [Related]
2. Dapagliflozin as monotherapy in drug-naive Asian patients with type 2 diabetes mellitus: a randomized, blinded, prospective phase III study.
Ji L; Ma J; Li H; Mansfield TA; T'joen CL; Iqbal N; Ptaszynska A; List JF
Clin Ther; 2014 Jan; 36(1):84-100.e9. PubMed ID: 24378206
[TBL] [Abstract][Full Text] [Related]
3. Dapagliflozin improves glycemic control and reduces body weight as add-on therapy to metformin plus sulfonylurea: a 24-week randomized, double-blind clinical trial.
Matthaei S; Bowering K; Rohwedder K; Grohl A; Parikh S;
Diabetes Care; 2015 Mar; 38(3):365-72. PubMed ID: 25592197
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of dapagliflozin in Asian patients with type 2 diabetes after metformin failure: A randomized controlled trial.
Yang W; Han P; Min KW; Wang B; Mansfield T; T'Joen C; Iqbal N; Johnsson E; Ptaszynska A
J Diabetes; 2016 Nov; 8(6):796-808. PubMed ID: 26589253
[TBL] [Abstract][Full Text] [Related]
5. Long-Term Safety of Dapagliflozin in Older Patients with Type 2 Diabetes Mellitus: A Pooled Analysis of Phase IIb/III Studies.
Fioretto P; Mansfield TA; Ptaszynska A; Yavin Y; Johnsson E; Parikh S
Drugs Aging; 2016 Jul; 33(7):511-22. PubMed ID: 27357173
[TBL] [Abstract][Full Text] [Related]
6. Effect of dapagliflozin on obstructive sleep apnea in patients with type 2 diabetes: a preliminary study.
Tang Y; Sun Q; Bai XY; Zhou YF; Zhou QL; Zhang M
Nutr Diabetes; 2019 Nov; 9(1):32. PubMed ID: 31685792
[TBL] [Abstract][Full Text] [Related]
7. Sodium glucose co-transporter 2 inhibitors and their mechanism for improving glycemia in patients with type 2 diabetes.
Davidson JA; Kuritzky L
Postgrad Med; 2014 Oct; 126(6):33-48. PubMed ID: 25414933
[TBL] [Abstract][Full Text] [Related]
8. The SGLT2 Inhibitor Dapagliflozin Significantly Improves the Peripheral Microvascular Endothelial Function in Patients with Uncontrolled Type 2 Diabetes Mellitus.
Sugiyama S; Jinnouchi H; Kurinami N; Hieshima K; Yoshida A; Jinnouchi K; Nishimura H; Suzuki T; Miyamoto F; Kajiwara K; Jinnouchi T
Intern Med; 2018 Aug; 57(15):2147-2156. PubMed ID: 29607968
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of dapagliflozin in Asian patients: A pooled analysis.
Yang W; Ji L; Zhou Z; Cain VA; Johnsson KM; Sjöström CD
J Diabetes; 2017 Aug; 9(8):787-799. PubMed ID: 27625142
[TBL] [Abstract][Full Text] [Related]
10. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin.
Bolinder J; Ljunggren Ö; Kullberg J; Johansson L; Wilding J; Langkilde AM; Sugg J; Parikh S
J Clin Endocrinol Metab; 2012 Mar; 97(3):1020-31. PubMed ID: 22238392
[TBL] [Abstract][Full Text] [Related]
11. [Dapagliflozin: Beyond glycemic control in the treatment of type 2 diabetes mellitus].
Sanz-Serra P; Pedro-Botet J; Flores-Le Roux JA; Benaiges D; Chillarón JJ
Clin Investig Arterioscler; 2015; 27(4):205-11. PubMed ID: 25648671
[TBL] [Abstract][Full Text] [Related]
12. Dapagliflozin: a new sodium-glucose cotransporter 2 inhibitor for treatment of type 2 diabetes.
Vivian EM
Am J Health Syst Pharm; 2015 Mar; 72(5):361-72. PubMed ID: 25694411
[TBL] [Abstract][Full Text] [Related]
13. Empagliflozin versus dapagliflozin in patients with type 2 diabetes inadequately controlled with metformin, glimepiride and dipeptidyl peptide 4 inhibitors: A 52-week prospective observational study.
Ku EJ; Lee DH; Jeon HJ; Oh TK
Diabetes Res Clin Pract; 2019 May; 151():65-73. PubMed ID: 30954510
[TBL] [Abstract][Full Text] [Related]
14. Dapagliflozin lowers plasma glucose concentration and improves β-cell function.
Merovci A; Mari A; Solis-Herrera C; Xiong J; Daniele G; Chavez-Velazquez A; Tripathy D; Urban McCarthy S; Abdul-Ghani M; DeFronzo RA
J Clin Endocrinol Metab; 2015 May; 100(5):1927-32. PubMed ID: 25710563
[TBL] [Abstract][Full Text] [Related]
15. Dapagliflozin significantly reduced liver fat accumulation associated with a decrease in abdominal subcutaneous fat in patients with inadequately controlled type 2 diabetes mellitus.
Kurinami N; Sugiyama S; Yoshida A; Hieshima K; Miyamoto F; Kajiwara K; Jinnouch K; Jinnouchi T; Jinnouchi H
Diabetes Res Clin Pract; 2018 Aug; 142():254-263. PubMed ID: 29859912
[TBL] [Abstract][Full Text] [Related]
16. Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trials.
Jabbour S; Seufert J; Scheen A; Bailey CJ; Karup C; Langkilde AM
Diabetes Obes Metab; 2018 Mar; 20(3):620-628. PubMed ID: 28950419
[TBL] [Abstract][Full Text] [Related]
17. Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: a randomized placebo-controlled trial.
Fadini GP; Bonora BM; Zatti G; Vitturi N; Iori E; Marescotti MC; Albiero M; Avogaro A
Cardiovasc Diabetol; 2017 Apr; 16(1):42. PubMed ID: 28376855
[TBL] [Abstract][Full Text] [Related]
18. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.
Scheen AJ
Drugs; 2015 Jan; 75(1):33-59. PubMed ID: 25488697
[TBL] [Abstract][Full Text] [Related]
19. Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin.
Hayashi T; Fukui T; Nakanishi N; Yamamoto S; Tomoyasu M; Osamura A; Ohara M; Yamamoto T; Ito Y; Hirano T
Cardiovasc Diabetol; 2017 Jan; 16(1):8. PubMed ID: 28086872
[TBL] [Abstract][Full Text] [Related]
20. Dapagliflozin reduces thrombin generation and platelet activation: implications for cardiovascular risk reduction in type 2 diabetes mellitus.
Kohlmorgen C; Gerfer S; Feldmann K; Twarock S; Hartwig S; Lehr S; Klier M; Krüger I; Helten C; Keul P; Kahl S; Polzin A; Elvers M; Flögel U; Kelm M; Levkau B; Roden M; Fischer JW; Grandoch M
Diabetologia; 2021 Aug; 64(8):1834-1849. PubMed ID: 34131781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
